Replies to post #1963 on SurModics Inc (SRDX)

[DewDiligence]

Thanks, DoA, for the webcast annotations and hyperlinks.

>…those interested in siRNA as an anti-VEGF therapy may be interested in the comments concerning AGN-745 [a.k.a. Sirna-027] albeit they were characteristically brief.<

The comments were notable in their omission of any information of consequence. In fact, in the almost three years since AGN inked its AMD deal with Sirna Therapeutics (#msg-7926760), AGN has probably devoted less than five minutes in total to discussing this program.

I think it’s reasonable to infer that standalone Sirna-027 doesn’t work well enough to form the basis of a commercial AMD program in the Lucentis era.

Moreover, I think we can probably put to rest the notion that MRK is thinking of marrying Sirna-027 to I-vation. Here’s what I said about this a year ago (#msg-20924124):

>>
…MRK could yet be interested in marrying Sirna-027 to I-vation. Investors have a simple way to track this: If MRK does not make a move to buy out AGN’s interest in Sirna-027 fairly soon, it almost certainly means that MRK is not contemplating a Sirna-027+I-vation combination.
<<

Regards, Dew

p.s. I thought the most promising program from a commercial standpoint that AGN talked about was the one using Lumigan to enhance eyelashes: #msg-29857899.